NEUROPEPTIDE · ACTH(4-7)PGP · INTERACTIVE LITERATURE WALKTHROUGH
Semax, demonstrated.
Seventeen findings from the peer-reviewed literature, organized as a guided walkthrough — mechanism, pharmacokinetics, neuroprotection, and the Russian regulatory chapter, all in one place.
The short version
Semax (ACTH(4-7)PGP) is a synthetic, seven-amino-acid peptide developed in Soviet-era Russia and registered as a prescription drug there for stroke and cognitive impairment. It is not FDA-approved and not sold as a medicine in the US or EU — it circulates as a research chemical outside Russia.
What does the science show? Primarily two things. First, it reliably triggers production of BDNF (brain-derived neurotrophic factor) in rodent brain tissue — a protein associated with neuron survival and learning. Second, in animal stroke models it dials down inflammatory gene programs and limits damage to brain tissue around the injury site. Neither effect is yet confirmed in Western human randomized trials.
People researching it describe mental clarity and quiet focus — more "organized thoughts" than stimulant energy, and typically lasting only a few hours. A real minority notice nothing. Read the full effects walkthrough for what the community reports alongside the cited cautions. This site reviews the published literature systematically, with every claim traced to a numbered citation.
What is Semax?
Semax is a synthetic heptapeptide — a chain of seven amino acids (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4-7 fragment of adrenocorticotropic hormone (ACTH). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been registered as a pharmaceutical drug in the Russian Federation since the 1990s, where it is classified as a nootropic and neuroprotective agent for ischemic stroke and cognitive impairment [15].
The peptide carries a molecular weight of 887.0 Da. Its structure is not a simple ACTH fragment: researchers appended a C-terminal Pro-Gly-Pro (PGP) tripeptide to the ACTH(4-7) tetrapeptide to confer resistance to peptidase degradation — a practical engineering choice that extends biological activity without altering the core pharmacophore [13]. The resulting compound crosses the blood-brain barrier following intranasal administration, with intact Semax detectable in rat brain tissue within two minutes and biological effects measurable 20-24 hours after a single dose [13].
Outside Russia, Semax has not received approval from the FDA, EMA, or equivalent agencies. It is the subject of an active preclinical and in vitro research literature — more than 40 publications indexed on PubMed — and new findings emerged in both 2024 and 2025. This site reviews that literature systematically.
How does Semax work? The core mechanism
Semax does not operate through a single receptor. The research literature describes a convergent set of pathways centered on two main axes: upregulation of neurotrophic factor synthesis and suppression of neuroinflammatory gene cascades.
The best-documented mechanism is rapid BDNF (brain-derived neurotrophic factor) induction. After intranasal delivery in rats, Semax at 50 microg/kg produced measurable BDNF protein increases in the basal forebrain within three hours, with effects sustained over 24 hours [1]. The same dose induced gene-level changes — upregulating BDNF and NGF mRNA in the hippocampus, brainstem, and cerebellum within one hour of administration, with region-specific modulation: frontal cortex NGF actually decreased, suggesting Semax acts on neurotrophin transcription in a spatially selective rather than globally diffuse manner [2].
The anti-inflammatory arm is equally well documented. In rodent stroke models, Semax at 100 microg/kg reduced phosphorylated JNK (the stress kinase that drives neuronal apoptosis) by more than 1.5-fold in cortex and subcortex, and simultaneously increased pCREB (the plasticity-associated transcription factor) by more than 1.5-fold in subcortical structures [4]. MMP-9 and c-Fos, two markers of inflammatory signaling, were also reduced by more than 1.5-fold in the frontoparietal cortex [4].
A 2014 genome-wide transcriptional analysis added detail to the immunomodulatory picture: in a focal cerebral ischemia rat model, Semax altered expression of 96 genes at three hours and 68 genes at 24 hours post-stroke, with more than half of all altered genes involved in immune processes [5]. The affected gene programs included chemokines (CXCL13, CXCL9, CXCL10, CCL5, CCL7, CCL19) and 24 vascular genes at the three-hour mark [5].
Serotonergic and dopaminergic circuits also feature in the literature. Semax elevated striatal 5-HIAA (the primary serotonin metabolite) in rodents, and when co-administered with D-amphetamine in experimental conditions, potentiated extracellular dopamine levels and locomotor activity beyond what amphetamine produced alone [16]. This bidirectional monoamine modulation is consistent with the nootropic and mood-modulating profile reported in the Russian clinical literature.
The most recent mechanistic additions come from in vitro and copper-chelation work. Semax forms high-affinity Cu2+ complexes (conditional dissociation constant 1.3 x 10^-15 M), stripping copper from amyloid-beta aggregates — a mechanism with potential relevance to Alzheimer's disease research [9].
Pharmacokinetics: what happens after intranasal delivery?
The intranasal route is both the primary clinical route and the best-studied route in the pharmacokinetic literature. In a radiolabeled tracking study in rats, 0.093% of total administered radioactivity per gram of brain tissue was detected within two minutes of intranasal dosing at 50 microg/kg, and approximately 80% of that signal represented intact, unmetabolized Semax [13]. The blood-brain barrier penetration is rapid by peptide standards.
Metabolic conversion begins quickly. By one hour post-administration, the Pro-Gly-Pro metabolite — the C-terminal tripeptide that was engineered into Semax specifically for its peptidase resistance — had become the predominant species in brain tissue [13]. Importantly, biological effects (measurable neurotrophin gene changes, BDNF protein elevation) persist 20-24 hours despite the rapid clearance of the parent peptide. This persistence suggests that receptor-mediated downstream signaling sustains the biological response well beyond the half-life of the parent compound itself.
In rodent studies, both intranasal and intraperitoneal routes have been used. The intraperitoneal route dominates the stroke and ischemia literature (typically 100 microg/kg at defined post-occlusion time points). Intranasal delivery — the clinically relevant route — dominates the neurotrophin, cognitive, and Alzheimer's-model literature. No validated human pharmacokinetic data has been published in Western peer-reviewed journals.
The PGP tripeptide contributes to biological activity independently: PGP itself has been studied as a separate compound with anti-inflammatory and neuroprotective properties [3], and its emergence as the dominant brain-tissue species at one hour post-dosing complicates any attempt to attribute specific downstream effects solely to the parent Semax molecule.
What the research shows: a quick orientation
The published literature covers four main areas, each supported by multiple independent studies:
Neuroprotection in stroke models. Multiple rodent studies using the tMCAO (transient middle cerebral artery occlusion) model document Semax's ability to limit ischemic gene disruption, suppress neuroinflammation, and preserve penumbral tissue [3][4][5][6][7][17]. The 2021 protein expression study confirmed broad intracellular protection across multiple pathways simultaneously [4].
Neurotrophic factor induction. BDNF, NGF, and NT-3 upregulation across multiple brain regions, studied in intact animals and in ischemia models [1][2][3]. The BDNF induction is rapid (protein-level change within three hours, mRNA within one hour) and region-selective.
Antidepressant-like and antistress profile. A 2024 study in rats subjected to chronic unpredictable stress found that Semax at 60 nmol/kg daily reversed anhedonia, body weight suppression, adrenal hypertrophy, and hippocampal BDNF reduction [10] — a convergent result consistent with the compound's BDNF-induction mechanism.
Alzheimer's disease-relevant mechanisms. Two studies (2022 and 2025) document Semax's capacity to chelate copper from amyloid-beta complexes in vitro, reducing amyloid fiber formation by up to 90% and cutting amyloid-beta-induced neuronal toxicity [9]. A 2025 transgenic Alzheimer's mouse study found that intranasal Semax at 50 microg/kg (every other day for one month) reduced cortical amyloid plaque load by 2.8-fold at 7.5 months and improved performance on multiple cognitive behavioral tests [11].
For the full organized walkthrough — each finding as a numbered step-card with dose, species, route, and citation — proceed to the research page.